PRECIGEN, INC. Restricted Cash, Current
PRECIGEN, INC. (PGEN) had Restricted Cash, Current of $263.00 thousand as of 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Cash Equivalent, Current
us-gaap:RestrictedCashCurrent · last filed 2024-08-14
- 2024-06-30: Restricted Cash, Current $263.00K.
- 2023-12-31: Restricted Cash, Current $0.00.
- 2023-09-30: Restricted Cash, Current $0.00.
- 2023-06-30: Restricted Cash, Current $0.00.
| Period end | Restricted Cash, Current |
|---|---|
| 2024-06-30 | $263.00K 10-Q · filed 2024-08-14 |
| 2023-12-31 | $0.00 10-Q · filed 2024-08-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $13.80M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $43.34M 10-K · filed 2024-03-19 |
| 2022-09-30 | $82.44M 10-Q · filed 2022-11-09 |
| 2022-03-31 | $13.80M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |